BioAge Labs, Inc. (NASDAQ:BIOA) Sees Large Drop in Short Interest

BioAge Labs, Inc. (NASDAQ:BIOA) was the recipient of a large decrease in short interest during the month of January. As of January 30th, there was short interest totaling 909,129 shares, a decrease of 16.3% from the January 15th total of 1,085,882 shares. Currently, 3.2% of the shares of the stock are sold short. Based on an average trading volume of 919,863 shares, the short-interest ratio is currently 1.0 days. Based on an average trading volume of 919,863 shares, the short-interest ratio is currently 1.0 days. Currently, 3.2% of the shares of the stock are sold short.

BioAge Labs Trading Down 1.9%

Shares of BIOA opened at $19.57 on Tuesday. The firm has a market cap of $701.58 million, a price-to-earnings ratio of -12.88 and a beta of 1.40. The stock has a 50 day moving average of $16.77 and a 200-day moving average of $9.94. BioAge Labs has a 52 week low of $2.88 and a 52 week high of $24.00.

Insider Activity

In other BioAge Labs news, insider Paul D. Rubin sold 7,433 shares of the business’s stock in a transaction on Monday, February 2nd. The stock was sold at an average price of $18.75, for a total value of $139,368.75. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. Also, CFO Dov A. Md Goldstein sold 27,000 shares of the stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $19.70, for a total value of $531,900.00. Following the transaction, the chief financial officer owned 22,408 shares in the company, valued at $441,437.60. This trade represents a 54.65% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 354,437 shares of company stock worth $5,813,228 over the last ninety days. 20.82% of the stock is currently owned by insiders.

Institutional Trading of BioAge Labs

A number of institutional investors and hedge funds have recently modified their holdings of the business. Police & Firemen s Retirement System of New Jersey acquired a new stake in BioAge Labs in the second quarter worth $27,000. Russell Investments Group Ltd. bought a new position in shares of BioAge Labs during the third quarter worth about $27,000. CWM LLC increased its holdings in shares of BioAge Labs by 39.9% in the 4th quarter. CWM LLC now owns 3,693 shares of the company’s stock worth $49,000 after acquiring an additional 1,053 shares during the period. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its position in BioAge Labs by 85.6% in the 2nd quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 12,955 shares of the company’s stock valued at $54,000 after purchasing an additional 5,976 shares during the last quarter. Finally, Intech Investment Management LLC bought a new stake in BioAge Labs in the 2nd quarter valued at about $60,000.

Analysts Set New Price Targets

Several research firms have recently weighed in on BIOA. Morgan Stanley set a $23.00 price objective on BioAge Labs in a research note on Wednesday, February 4th. Weiss Ratings restated a “sell (d-)” rating on shares of BioAge Labs in a report on Tuesday, January 27th. Wall Street Zen upgraded shares of BioAge Labs from a “sell” rating to a “hold” rating in a research note on Tuesday, February 3rd. Piper Sandler started coverage on shares of BioAge Labs in a research note on Tuesday, January 27th. They issued an “overweight” rating on the stock. Finally, Citigroup lifted their target price on shares of BioAge Labs from $10.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, October 29th. Two analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, BioAge Labs presently has a consensus rating of “Hold” and a consensus price target of $19.00.

About BioAge Labs

BioAge Labs (NASDAQ: BIOA) is a clinical-stage biotechnology company focused on discovering and developing therapies that address age-associated diseases. The company leverages its proprietary analytics platform to mine large-scale human biological data for insights into the molecular mechanisms of aging. By targeting fundamental aging pathways, BioAge aims to create interventions that extend healthspan and treat conditions that disproportionately affect older populations.

At the core of BioAge’s operations is its integrated drug discovery platform, which combines human omics datasets, machine learning algorithms and experimental validation to identify novel drug targets.